No Data
No Data
William Blair Maintains Cabaletta Bio(CABA.US) With Buy Rating
Cabaletta Bio Advances T Cell Therapies for Autoimmune Diseases
Cabaletta Bio Is Maintained at Equal-Weight by Wells Fargo
Stifel Maintains Cabaletta Bio(CABA.US) With Buy Rating, Cuts Target Price to $13
Wells Fargo Maintains Cabaletta Bio(CABA.US) With Hold Rating, Cuts Target Price to $3
Cabaletta Bio Is Maintained at Buy by UBS